JP6669731B2 - がん患者由来のヒト血清のエクソソーム画分からのアスパルチル（アスパラギニル）ベータヒドロキシラーゼ（ｈａａｈ）の回収 - Google Patents

がん患者由来のヒト血清のエクソソーム画分からのアスパルチル（アスパラギニル）ベータヒドロキシラーゼ（ｈａａｈ）の回収 Download PDF

Info

Publication number
JP6669731B2
JP6669731B2 JP2017513644A JP2017513644A JP6669731B2 JP 6669731 B2 JP6669731 B2 JP 6669731B2 JP 2017513644 A JP2017513644 A JP 2017513644A JP 2017513644 A JP2017513644 A JP 2017513644A JP 6669731 B2 JP6669731 B2 JP 6669731B2
Authority
JP
Japan
Prior art keywords
haah
exosomes
cancer
serum
elisa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017513644A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526931A5 (enExample
JP2017526931A (ja
Inventor
マーク セメナック，
マーク セメナック，
ホッセイン ガンバリ，
ホッセイン ガンバリ，
マイケル レボウィッツ，
マイケル レボウィッツ，
Original Assignee
パナシア ファーマシューティカルズ， インコーポレイテッド
パナシア ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パナシア ファーマシューティカルズ， インコーポレイテッド, パナシア ファーマシューティカルズ， インコーポレイテッド filed Critical パナシア ファーマシューティカルズ， インコーポレイテッド
Publication of JP2017526931A publication Critical patent/JP2017526931A/ja
Publication of JP2017526931A5 publication Critical patent/JP2017526931A5/ja
Application granted granted Critical
Publication of JP6669731B2 publication Critical patent/JP6669731B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2017513644A 2014-09-12 2015-09-14 がん患者由来のヒト血清のエクソソーム画分からのアスパルチル（アスパラギニル）ベータヒドロキシラーゼ（ｈａａｈ）の回収 Expired - Fee Related JP6669731B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462049582P 2014-09-12 2014-09-12
US62/049,582 2014-09-12
PCT/US2015/049976 WO2016040941A1 (en) 2014-09-12 2015-09-14 Recovery of aspartyl (asparaginyl) beta hydroxylase (haah) from an exosomal fraction of human sera from cancer patients

Publications (3)

Publication Number Publication Date
JP2017526931A JP2017526931A (ja) 2017-09-14
JP2017526931A5 JP2017526931A5 (enExample) 2018-09-06
JP6669731B2 true JP6669731B2 (ja) 2020-03-18

Family

ID=55454511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513644A Expired - Fee Related JP6669731B2 (ja) 2014-09-12 2015-09-14 がん患者由来のヒト血清のエクソソーム画分からのアスパルチル（アスパラギニル）ベータヒドロキシラーゼ（ｈａａｈ）の回収

Country Status (5)

Country Link
US (2) US20160077098A1 (enExample)
EP (1) EP3191841A4 (enExample)
JP (1) JP6669731B2 (enExample)
CA (1) CA2961004A1 (enExample)
WO (1) WO2016040941A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190049455A1 (en) * 2017-08-11 2019-02-14 Panacea Pharmaceuticals Inc. HAAH and MMP-9 are Complementary Cancer Biomarkers and Predictors of Metastasis when Combined
CN107907689A (zh) * 2017-10-10 2018-04-13 北京大学 外泌体蛋白cd5l的检测方法
CN111269986A (zh) * 2020-03-24 2020-06-12 江西惠肽生物科技有限公司 外泌体中asph基因在肺癌早期诊断试剂盒中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
WO2007087646A2 (en) * 2006-01-27 2007-08-02 Panacea Pharmaceuticals, Inc. Methods of diagnosing, predicting therapeutic efficacy and screening for new therapeutic agents for leukemia
US20090298097A1 (en) * 2007-07-17 2009-12-03 Harris Pamela J Methods for the diagnosis of lung cancer
EP3181705A1 (en) * 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
US20130178383A1 (en) * 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
CN103237901B (zh) * 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
CA2827894A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
KR20140136805A (ko) * 2013-05-21 2014-12-01 건국대학교 산학협력단 신규한 인간 엑소좀 단백질 및 그 용도

Also Published As

Publication number Publication date
EP3191841A4 (en) 2018-03-14
WO2016040941A1 (en) 2016-03-17
US20210148915A9 (en) 2021-05-20
JP2017526931A (ja) 2017-09-14
EP3191841A1 (en) 2017-07-19
CA2961004A1 (en) 2016-03-17
US20180203013A1 (en) 2018-07-19
US20160077098A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
Gao et al. A novel strategy for facile serum exosome isolation based on specific interactions between phospholipid bilayers and TiO 2
Li et al. Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead‐Assisted Flow Cytometry Detection of Tumor‐Derived Extracellular Vesicles
AU2011241174B2 (en) Method and kit for cancer diagnosis
CN105934670A (zh) 用于分离外泌体的方法
Yang et al. Bead‐Based Extracellular Vesicle Analysis Using Flow Cytometry
CN110873711B (zh) 一种基于全自动化学发光分析仪的血清tk1检测试剂盒
WO2010101047A1 (ja) 子宮内膜症の判定方法、および子宮内膜症の診断用キット
Hu et al. Noninvasive diagnosis of nasopharyngeal carcinoma based on phenotypic profiling of viral and tumor markers on plasma extracellular vesicles
WO2024001044A1 (zh) 一种与肺癌相关的生物标志物组合、含其的试剂盒及其用途
CN108802389B (zh) 一种用于早期非小细胞肺癌诊断的试剂盒
JP6669731B2 (ja) がん患者由来のヒト血清のエクソソーム画分からのアスパルチル（アスパラギニル）ベータヒドロキシラーゼ（ｈａａｈ）の回収
JP2018528441A (ja) 非小細胞肺癌診断用タンパク質バイオマーカーパネル及びこれを用いた非小細胞肺癌診断方法
CN104678110A (zh) 一种血清cenpf抗体定量检测试剂盒
JP7449530B2 (ja) 腎癌の検出方法及び検査薬
CN107110848B (zh) 以脱氧羟腐胺缩赖氨酸合酶基因作为指标使用的动脉硬化及癌的检测方法
JPWO2008032868A1 (ja) 腎癌の腫瘍マーカー及び腎癌の罹患の識別方法
JP2015169608A (ja) 癌の検査方法
WO2021246153A1 (ja) 膵臓がんの検出方法及び検出試薬
JP6760562B2 (ja) 卵巣明細胞癌患者の予後を予測するための情報提供方法
CN116298323B (zh) 一种用于诊断狼疮性肾炎的生物标志物及应用
WO2021100621A1 (ja) がんの骨転移を検出する方法及び検出試薬
KR20230018174A (ko) 대장암 진단용 통합 자기 전기화학장치 및 그 방법
WO2010134567A1 (ja) 血中遊離核酸の検出方法
CN112180099A (zh) 子宫内膜异位症血清标志物的应用
WO2019112056A1 (ja) 神経膠腫の予測方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180724

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200227

R150 Certificate of patent or registration of utility model

Ref document number: 6669731

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees